Key facts
- Recross Cardio’s last known valuation is $13.0M (Jun 2025).
- It has raised $6.8M; the latest was Early Stage VC ($4.7M) in Jun 2025.
- Notable investors include LIFTT.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Recross Cardio
- ·The full record, as it builds
Funding rounds
No funding rounds for Recross Cardio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Recross Cardio
Developer of novel septal closure membrane intended to function as a scaffold. The company's septal occluder preserves access to the left heart using a patented polymer skin, enabling patients to recover, leveraging their healing response to leave behind a compliant neo-septum.
- Sector
- Healthcare
- HQ
- Dover, DE, United States
- Founded
- 2021
- Employees
- 5
- Website
- recrosscardio.com/
- Ownership
- Privately Held (backing)
Recross Cardio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Recross Cardio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Recross Cardio in its N-PORT filings yet. We sweep new filings monthly.